- Home
- AENT vs LUNG Comparison
AENT vs LUNG Comparison
Compare AENT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- LUNG
- Stock Information
- Founded
- AENT 1990
- LUNG 1995
- Country
- AENT United States
- LUNG United States
- Employees
- AENT N/A
- LUNG N/A
- Industry
- AENT Durable Goods
- LUNG Industrial Specialties
- Sector
- AENT Consumer Discretionary
- LUNG Health Care
- Exchange
- AENT Nasdaq
- LUNG Nasdaq
- Market Cap
- AENT 161.5M
- LUNG 124.0M
- IPO Year
- AENT N/A
- LUNG 2020
- Fundamental
- Price
- AENT $5.21
- LUNG $2.87
- Analyst Decision
- AENT Strong Buy
- LUNG Buy
- Analyst Count
- AENT 1
- LUNG 6
- Target Price
- AENT $10.00
- LUNG $11.53
- AVG Volume (30 Days)
- AENT 46.9K
- LUNG 318.2K
- Earning Date
- AENT 05-15-2025
- LUNG 07-30-2025
- Dividend Yield
- AENT N/A
- LUNG N/A
- EPS Growth
- AENT N/A
- LUNG N/A
- EPS
- AENT 0.23
- LUNG N/A
- Revenue
- AENT $1,072,641,000.00
- LUNG $87,473,000.00
- Revenue This Year
- AENT $4.77
- LUNG $18.02
- Revenue Next Year
- AENT N/A
- LUNG $18.17
- P/E Ratio
- AENT $22.79
- LUNG N/A
- Revenue Growth
- AENT N/A
- LUNG 19.84
- 52 Week Low
- AENT $1.10
- LUNG $2.50
- 52 Week High
- AENT $11.57
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- AENT 68.76
- LUNG 39.07
- Support Level
- AENT $5.17
- LUNG $2.62
- Resistance Level
- AENT $6.37
- LUNG $2.88
- Average True Range (ATR)
- AENT 0.54
- LUNG 0.17
- MACD
- AENT 0.14
- LUNG 0.05
- Stochastic Oscillator
- AENT 65.39
- LUNG 39.68
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.